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Evidence and guidelines provide conﬂicting recommendations regarding the use of aspirin for primary
prevention of cardiovascular disease, particularly in geriatric patients with diabetes. The objective of this
study is to identify aspirin-prescribing patterns and determine if it is consistent with the 2013 American
Diabetes Association and American Geriatrics Association guidelines. A survey was distributed to
attending physicians, fellow physicians, and mid-level practitioners in internal medicine, geriatric, car-
diology, and endocrinology clinics in Detroit, MI, USA. Most providers (88%) indicated that they would
give aspirin for primary prevention of cardiovascular disease. Of those who chose to give aspirin, all
chose to prescribe a dose of 81 mg. Most providers elected to prescribe aspirin based on patient age (86%)
and comorbidities (98%). Aspirin is routinely prescribed for geriatric patients with diabetes for the pri-
mary prevention of cardiovascular disease. The guidelines provide conﬂicting recommendations;
therefore, provider education is needed to guide decision-making in the elderly.
Copyright © 2016, Asia Paciﬁc League of Clinical Gerontology & Geriatrics. Published by Elsevier Taiwan
LLC. This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/
by-nc-nd/4.0/).1. Introduction
For decades, antiplatelet therapy has been the mainstay of
therapy for the prevention of cardiovascular disease (CVD). Aspirin
is the antiplatelet drug of choice and has well documented beneﬁts
in secondary CVD prevention. The use of aspirin for primary pre-
vention remains controversial due to conﬂicting results from clin-
ical trials and meta-analyses.1e5 A variety of national organizations
provide guidance on utilizing aspirin for primary CVD pre-
vention.6e13 Historically, these guidelines have provided a favorable
recommendation for using aspirin, although more recently there is
growing controversy surrounding aspirin for this indication.
There are limited data for primary CVD prevention speciﬁcally
for geriatric patients with diabetes. In the USA, it is estimated that
more than 10 million people older than 65 years have diabetes,ge of Pharmacy and Health
igan 48201, USA.
d).
inical Gerontology & Geriatrics. Pub
d/4.0/).which includes almost 27% of all people in the geriatric age group.14
Geriatric patients with diabetes are at high risk for CVD events such
as myocardial infarction and stroke. Treatment with aspirin may
provide a protective beneﬁt. However, increasing age also increases
the risk for adverse events associated with daily aspirin therapy,
such as bleeding. There is a ﬁne balance between the risks and
beneﬁts of aspirin for primary CVD prevention in geriatric patients
with diabetes. Both the American Diabetes Association (ADA) and
the American Geriatrics Association (AGS) have published guide-
lines on the care of patients with diabetes that include recom-
mendations on the use of aspirin.6,7 The ADA guidelines
recommend aspirin for primary prevention if the patient's 10-year
CVD risk score is  10%.6 The AGS states that aspirin for primary
CVD prevention is not recommended for patients  65 years with
diabetes.7
As a result of different guideline recommendations, providers
caring for geriatric patients with diabetes may have differing pre-
scribing patterns. Our hypothesis was that these recommendations
might produce greater uncertainty in trainees than established
practitioners. Thus, the purposes of this study were: (1) to identifylished by Elsevier Taiwan LLC. This is an open access article under the CC BY-NC-ND
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geriatric patients with diabetes according to practitioner experi-
ence; and (2) to determine how current prescribing patterns
compare with the ADA and AGS guidelines.
2. Methods
The study was approved by the Investigational Review Board at
Wayne State University, Detroit, MI, USA and was conducted at
various outpatient clinics and inpatient sites within the Detroit
Medical Center (DMC; Detroit, MI, USA). Our experienced practi-
tioner group consisted of attending physicians and midlevel pro-
viders (nurse practitioners) at the DMC. The trainee group consisted
of residents and fellows enrolled in United States-accredited grad-
uate medical education training programs at the DMC.
We created a survey to assess provider preferences on pre-
scribing aspirin for primary CVD prevention in elderly patients with
diabetes. Surveys were distributed to providers at staff meetings
and small group educational meetings. The following specialties
were surveyed: cardiology, endocrinology, geriatrics, and internal
medicine. At the beginning of the study, surveys were distributed to
attending physicians, fellows and residents, and mid-level practi-
tioners. Surveys were also distributed to internal medicine resident
physicians at the end of their rotations.
The following case was given to providers taking the survey. A
68-year-old white woman (MB) is in your ofﬁce for follow-up of her
chronic medical conditions. She has hypertension, hyperlipidemia,
and type 2 diabetes mellitus. She has a family history of hyper-
tension (mother and father) and type 2 diabetes mellitus (father).
The patient is independent at home and her physical activity is
walking her dog. She denies the use of tobacco, alcohol, and illicit
drugs. Currently she is taking guideline recommended medications
to manage her comorbidities. Her blood pressure, lipids, and dia-
betes are at goal.
The survey was estimated to take 5e10 minutes. There were a
total of 15 questions in a combination of multiple-choice and free-
text formats. The survey consisted of two components: (1) ﬁve
questions pertaining to demographics of the providers and (2) a
patient case with 10 clinical questions related to the case. These
questions allowed three possible answers; yes, no, or uncertain.
Analysis was performed using nonparametric testing of the
following: aspirin prescribing patterns between physicians and
mid-level practitioners versus trainees. Chi-square analyses or
Fisher exact tests (cell-size dependent) were used to compare
categorical variables. For presentation of the results, we combinedTable 1
Response rates for survey questions.
Question or item
Which of the following most accurately describes your current level of practice?
Which of the following most accurately describes your area of specialty?
If you are a resident physician, which service are you currently covering?
Would you recommend MB take aspirin for primary prevention of cardiovascular dis
If you recommend MB take aspirin for primary prevention of cardiovascular disease,
Please indicate the reason(s) for your choice. You may list as many reasons as you w
Your recommendation, everything being the same as original case, except:
- MB's blood pressure is 156/80 mmHg
- MB's fasting lipid panel is TC, 178 mg/dL; TG, 78 mg/dL; HDL, 42 mg/dL; LDL, 120
- MB's A1C is 8%
- MB has a history of GI ulceration with bleeding 5 years ago
- MB is a smoker
- MB is older with an age of 75 years
- MB is older with an age of 85 years
- MB is male instead of female
Comments
GI ¼ gastrointestinal; HDL ¼ high-density lipoprotein; LDL ¼ low-density lipoprotein;the no and uncertain answers, thus 2  2 contingency tables were
analyzed.
3. Results
There was 100% response rate with a total of 48 providers who
completed the survey. Attending physicians (29.2%) practiced in
internal medicine (4.2%), geriatrics (12.5%), cardiology (8.3%), and
endocrinology (4.2%). Trainee specialties were all internal medicine
residents (58.3%) on rotation for one of the above specialties, or
geriatrics fellows (8.3%). Midlevel practitioners were nurse practi-
tioners in geriatrics (4.2%). Responses to all questions were not
mandatory, thus response rates to survey questions differed
(Table 1).
Most providers (42 of 48; 88%) indicated that they would pre-
scribe aspirin for primary CVD prevention in a geriatric patient with
diabetes (Table 2). However, only trainees indicated that they
would not give aspirin or were uncertain. Of the respondents who
chose to give aspirin, all indicated that a dose of 81 mg was
preferred. The providers were asked to indicate reasons to give or
not give aspirin. Most of them selected age (86%) and comorbidities
(98%) as the rationale behind their decision. Others chose sex, race,
family, bleeding history, and lifestyle as their reasoning. A majority
of respondents indicated theywould prescribe aspirin if the patient
met any of the following criteria: elevated blood pressure (98%),
elevated LDL (92%), elevated A1C (100%), smoking (98%), or male
sex (100%). There were no differences in experience-related aspirin
treatment recommendations for these criteria.
Responses varied between providers if there was a history of
gastrointestinal ulceration and bleeding (overall, 50% yes), and if
the patient's age increased over 68 years old (overall, 77% yes if age
75 years and 48% yes if age 85 years). Furthermore, in the case of
prior gastrointestinal bleeding, there was evidence that prescribing
patterns differed: more trainees recommended aspirin (p ¼ 0.01).
Although there was no evidence from the 2  2 contingency table
analysis for a difference in the experience-related prescribing
pattern based on patient age (Table 2), there was weak evidence
within both groups that aspirin recommendations decreased as age
increased from 75 years to 85 years; experienced providers p ¼
0.08; trainees p ¼ 0.06.
4. Discussion
We identiﬁed through a self-reported survey that most pro-
viders would give aspirin for primary CVD prevention. There isRespondents
Total n ¼ 48, n (%)
48 (100.0)
48 (100.0)
28 (58.3)
ease? 48 (100.0)
which dose do you recommend? 43 (89.6)
ish. 43 (89.6)
mg/dL
48 (100.0)
2 (0.04)
TC ¼ total cholesterol; TG ¼ triglycerides.
Table 2
Response rates to the survey questionnaire.
Question Established practitioners (Attending physicians & mid-level providers) n (%) Trainees (fellow and resident physicians) n (%) p
1. Would you recommend MB take aspirin for primary prevention of cardiovascular disease?
Yes 16 (100) 26 (81) 0.06
No 0 (0) 0 (0)
Uncertain 0 (0) 6 (19)
2. If you recommend MB take aspirin for primary prevention of cardiovascular disease, which dose do you recommend?
81 mg daily 16 (100) 26 (100) NSa
> 81 mg daily 0 (0) 0 (0)
Please indicate the reason(s) for your choice. n**
Age 13 23
Sex 0 2
Race 0 0
Comorbidities 16 25
Family history 4 4
Bleeding history 2 0
Lifestyle 2 0
Other 0 0
3. Would you recommend MB take aspirin if her blood pressure were 156/80 mmHg?
Yes 16 (100) 31 (97) 0.51
No 0 (0) 1 (3)
Uncertain 0 (0) 0 (0)
4. Would you recommend MB take aspirin if her fasting lipid panel is TC, 178 mg/dL; TG, 78 mg/dL; HDL, 42 mg/dL; LDL, 120 mg/dL
Yes 16 (100) 28 (87) 0.14
No 0 (0) 4 (12)
Uncertain 0 (0) 0 (0)
5. Would you recommend MB take aspirin if her A1C were 8%?
Yes 16 (100) 32 (100) NSa
No 0 (0) 0 (0)
Uncertain 0 (0) 0 (0)
6. Would you recommend MB take aspirin if she has a history of GI ulceration with bleeding 5 years ago?
Yes 4 (25) 20 (63) 0.01
No 9 (56) 4 (13)
Uncertain 3 (19) 8 (25)
7. Would you recommend MB take aspirin if she were a smoker?
Yes 16 (100) 31 (97) 0.48
No 0 (0) 1 (3)
Uncertain 0 (0) 0 (0)
8. Would you recommend MB take aspirin if she were 75 years old?
Yes 11 (69) 26 (81) 0.33
No 5 (31) 2 (6)
Uncertain 0 (0) 4 (13)
9. Would you recommend MB take aspirin if she were 85 years old?
Yes 5 (31) 18 (56) 0.10
No 6 (31) 6 (19)
Uncertain 5 (69) 8 (25)
10. Would you recommend MB take aspirin if she were male instead of female?
Yes 16 (100) 32 (100) NSa
No 0 (0) 0 (0)
Uncertain 0 (0) 0 (0)
GI ¼ gastrointestinal; HDL ¼ high-density lipoprotein; LDL ¼ low-density lipoprotein; NS ¼ not signiﬁcant; TC ¼ total cholesterol; TG ¼ triglycerides.
a Only number is reported, as multiple options were available. Comparative statistics were not performed; p shows the results for analysis of 2  2 contingency tables in
which the answers no and uncertain were combined.
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aspirin for primary CVD prevention in patients with diabetes,
especially in the elderly. As of 2013, the AGS guidelines recommend
against the use of aspirin in patients with diabetes who are 65 years
of age and older.7 Alternatively, the ADA guidelines recommend
prescribing aspirin based on the 10-year CVD risk score.6 Therefore,
current practice guidelines for this population provide conﬂicting
recommendations.
In our survey case, the patient is 68 years and her CVD risk score
is 4%. Therefore, both guidelines would recommend against the use
of aspirin for the following reasons: the patient is older than
65 years, and CVD risk score is < 5%. However, 88% of respondents
indicated that they would prescribe aspirin. These ﬁndings suggest
that providers do not necessarily follow the AGS and ADA guide-
lines when making clinical decisions for aspirin therapy in geriatric
patients with diabetes.
We found a uniform response from both groups for aspirin use
for increased blood pressure, lipid and A1C levels, smoking history,and sex with an overall recommendation rate between 92% and
100%. Conversely, prescribing patterns varied between groups
when a medical history of gastrointestinal ulceration and bleeding
was present. Attending and midlevel practitioners were more
conservative, and less likely to prescribe aspirin to such patients,
whereas trainees were more likely to give aspirin. A potential
reason for this ﬁnding is that attending physicians and midlevel
practitioners are more critical of the risks versus beneﬁts of aspirin
and have more clinical experience.
We did ﬁnd, for both groups, a reduction in those recom-
mending aspirin as age increased. The Beers criteria for potentially
inappropriate therapy in older adults recommends against the use
of aspirin for primary prevention in octogenarians.9
There are both beneﬁts and risks of daily aspirin therapy for
primary CVD prevention. Aspirin increases bleeding risk by inhib-
iting gastroprotective prostaglandins. By contrast, aspirin offers
protection against CVD events by reducing platelet aggregation,
activation, and vasoconstriction. This leads to a lower risk of events,
L. Kokoska et al. / Journal of Clinical Gerontology & Geriatrics 7 (2016) 33e3636which are more commonly seen in elderly patients with diabetes.15
A patient-speciﬁc assessment must be performed and therapy
should be tailored based on the patient's age, CVD risk score, and
bleeding risk.
We recognize that our study has limitations. First, the sample
size is small and includes providers from only one geographic area.
Therefore, responses may have been inﬂuenced by similar practice
patterns. Second, the small sample size prevented us from exam-
ining whether specialty training inﬂuenced the responses; for
example, it is possible that those trained in geriatric medicine
might have provided response more in line with the guidelines.
Third, the survey given was based on a speciﬁc case scenario.
Hence, the ﬁndings may not be generalized across other scenarios,
because different cases could elicit different responses from the
same providers.
Our ﬁndings highlight differences between practice and guide-
lines. We propose that practitioners should receive more education
regarding the risks associated with aspirin therapy in the geriatric
population. The current literature is conﬂicting and prescribing
patterns appear inconsistent. More studies are warranted to better
guide decision making in primary CVD prevention, especially in the
vulnerable elderly.
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